Durable complete response of hepatocellular carcinoma after metronomic capecitabine

Tumori

Volumn 96, Issue 6, 2010, Pages 1028-1030

  Brandi, Giovanni ^a   De Rosa, Francesco ^a   Bolondi, Luigi ^a   Agostini, Valentina ^a   Di Girolamo, Stefania ^a   Nobili, Elisabetta ^a   Biasco, Guido ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antiangiogenic therapy; Capecitabine; Hepatocellular carcinoma; Metronomic chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; EPIRUBICIN; LIPIODOL ULTRAFLUIDO; UNCLASSIFIED DRUG;

ADULT; ANAMNESIS; ARTICLE; CANCER REGRESSION; CASE REPORT; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; MALE; NEOVASCULARIZATION (PATHOLOGY); TREATMENT RESPONSE; TUMOR VOLUME;

EID: 79551500015     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/548.6527     Document Type: Article

References (13)

1. Ho JW, Pang RW, Lau C, Sun CK, Yu WC, Fan ST, Poon RT: Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology, 44: 836-843, 2006.
2. Llovet JM, Ricci F, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359: 378-390, 2008.
3. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer, 4: 423-436, 2004.
4. Miller KD, Sweeney CJ, Sledge GW Jr: Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol, 19: 1195-1206, 2001.
5. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthney JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD: Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer, 101: 578-586, 2004.
6. Burroughs A, Hochhauser D, Meyer T: Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol, 5: 409-418, 2004.
7. Boige V, Raoul JL, Pignon J, Bouché O, Blanc JF, Dahan L, Jouve JL, Dupouy N, Ducreux M; Fédération Francophone de Cancérologie Digestive: Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer, 97: 862-867, 2007.
8. Park SH, Lee Y, Han SH, Kwon SY, Kwon OS, Kim SS, Kim JH, Park YH, Lee JN, Bang SM, Cho EK, Shin DB, Lee JH: Systemic chemotherapy with doxorubicin, cisplatin, and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer, 6: 3, 2006.
9. Brandi G, Fanello S, Piscaglia F, Falanga A, Balducci D, Vignoli A, Flori S, Costantini S, Andreone P, Morelli C, Bolondi L, Biasco G: Preliminary results of "metronomic" capecitabine treatment in advanced hepatocellular carcinoma (HCC). ILCA Annual Conference 2007, abstract P-162, 2007.
10. Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, Kerbel RS: Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood, 106: 3058-3061, 2005.
11. Emmenegger U, Kerbel RS: Five years of clinical experience with metronomic chemotherapy: achievements and perspectives. Onkologie, 30: 606-608, 2007.
12. Steinbild S, Arends J, Medinger M, Häring B, Frost A, Drevs J, Unger C, Strecker R, Hennig J, Mross K: Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients - results of a phase II study. Onkologie, 30: 629-635, 2007.
13. Brandi G, Agostini V, de Rosa F, Di Girolamo S, Nobili E, Morselli-Labate A, Bolondi L, Biasco G: Metronomic capecitabine in Child-Pugh A patients with unresectable hepatocellular carcinoma. ASCO 2010 Gastrointestinal Cancer Symposium, abstract 243, 2010.